Media releases

27 Mar 2025
Idorsia publishes its Annual Report 2024
17 Mar 2025
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
14 Mar 2025
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
04 Mar 2025
Idorsia announces financial results for 2024
26 Feb 2025
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
26 Feb 2025
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
26 Feb 2025
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
25 Feb 2025
Bondholders approve amended terms of the 2025 convertible bonds
12 Feb 2025
Idorsia publishes the resolutions for the upcoming bondholder meeting
15 Jan 2025
Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders
14 Jan 2025
Idorsia publishes an invitation to a bondholder meeting
13 Jan 2025
Idorsia to call for a bondholder meeting
20 Dec 2024
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
27 Nov 2024
Idorsia enters into exclusive negotiations for global rights to aprocitentan
11 Nov 2024
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
29 Oct 2024
Idorsia announces financial results for the first nine months of 2024
16 Oct 2024
New data on aprocitentan to be presented at the ASN Kidney Week 2024
17 Sep 2024
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
05 Sep 2024
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
02 Sep 2024
Amended terms of Idorsia’s 2024 convertible bonds become effective

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.